Blog
12 Articles
Research Highlights from ASCO GI 2026
The latest research on drugs targeting KRAS and new immuotherapy combinations were among the highlights of ASCO GI 2026.
New Neoadjuvant Treatment in Trials
Dr. Brian Wolpin provides an analysis of the latest data on a new neoadjuvant treatment for tumors that can be removed.
Rewinding 2025: A Year in Pancreatic Cancer Research
We take a look back at the research developments in 2025: KRAS, earlier detection and screening, vaccines, and clinical trials.
PASS-01 Trial Results: Filling the Gaps in Personalized Medicine
The PASS-01 trial results provide data to help clarify how the subtypes of pancreatic cancer respond to the two main treatment protocols.
Pancreatic Cancer Research Highlights from ASCO Annual Meeting
The 2025 ASCO meeting featured pancreatic cancer research including a new treatment modality and a new treatment combination.
Phase II/III Clinical Trial Recruiting Advanced Pancreatic Cancer Patients
Dr. Shalini Makawita is a primary investigator in a phase IIb/III immunotherapy clinical trial for advanced pancreatic cancer patients.
Testing a New Chemo and RNA Therapy Combination
Researchers are testing a new drug that binds to messenger RNA in combination with mFOLFIRINOX chemotherapy.
Adapting Chemotherapy Regimens for a Better Pancreatic Cancer Outcome
Researchers are comparing chemotherapy regimens for effectiveness before surgery, and whether switching treatments makes a difference.
Chemo and SBRT for Inoperable Pancreatic Cancer
For inoperable pancreatic cancer, researchers are comparing mFOLFIRINOX and SBRT with gemcitabine-based treatment regimens.
Reeducating Myself About Pancreatic Cancer
Martin Hynes knew all about pancreatic cancer–as a research director he worked on the development of Gemzar. He was able to have a Whipple and is doing well.
Endurance Athlete Enduring Pancreatic Cancer Treatment
After a stage IV pancreatic cancer diagnosis, Dr. Kevin Moore had cytoreductive surgery to remove the metastases in his abdomen.
A New Drug to Target Cancer Cell Enzymes
Researchers are testing a drug that targets the enzymes that help generate energy for cell division, to disrupt pancreatic cancer cell multiplication.